Precipio Inc logo

Precipio Inc(PRPO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$22.13
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PRPO

11/13/2026: PRPO (1-star) is currently NOT-A-BUY. Pass it for now.

Precipio Inc is a micro-cap diagnostics company focused on oncology, providing both clinical pathology services and proprietary HemeScreen testing kits. The company's main strength lies in its specialized, niche approach, which offers clinical value compared to generalized testing. Its primary growth story revolves around scaling the adoption of its HemeScreen technology within hospital networks. However, investors should consider significant risks, including intense competition from massive reference labs, historical cash burn, and ongoing share dilution. Precipio is best suited for speculative growth investors who can monitor the company's ability to achieve consistent commercial adoption and eventually turn profitable.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers growth potential through HemeScreen but faces significant execution risks.
Momentum investorWeak fitStrong fit only if there is a sustained upward price signal driven by material commercial wins.
Value investorWeak fitThe company is not currently profitable, making traditional value metrics difficult to apply.
Dividend investorWeak fitThe company does not pay dividends and retains all cash for operations.
Low-risk investorWeak fitHigh volatility and operational risks make this unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a micro-cap stock, price swings are frequent and can be severe.
Valuation riskHighLack of earnings makes valuation highly subjective and speculative.
Competition risk (Major Labs)HighMassive competitors like LH and DGX control most of the market and payer relationships.
Business qualityMedium / highThe company is still proving its business model sustainability.
Dividend incomeLow / noneNo dividend income is expected in the near term.
Execution riskHighScaling the HemeScreen product adoption requires successful execution in a crowded market.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 39.68M USD
Price to earnings Ratio -
1Y Target Price 19
Price to earnings Ratio -
1Y Target Price 19
Volume (30-day avg) 34.0K shares
Beta 1.44
52 Weeks Range 17.79 - 33.63
Updated Date 11/14/2026
52 Weeks Range 17.79 - 33.63
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -6.34%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PRPO receives a 2-star rating, supported by solid company fundamentals. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
PRPO has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+91.5%) and strong revenue growth (+50.6%) are partially offset by soft cash generation (FCF margin 1.5%), weak profitability (net margin -1.5%).

Financial Health Rating

★★★★★
PRPO's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 10.7%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is PRPO's strongest growth driver at +91.5% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+50.6%, strong) and free-cash-flow growth (+66.2%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 19.5% and approximately 78.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.07% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 2.58%
BlackRock Inc 1.94%
Geode Capital Management, LLC 1.04%
Renaissance Technologies Corp 0.90%
Citadel Advisors Llc 0.82%

Unit Economics (Per $1K Revenue)

★★★★★
PRPO generates approximately $445 of gross profit, $-50 of operating income, and $15 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
PRPO has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Laboratory ServicesSpecialized pathology, hematopathology, and molecular testing services provided to clinicians.They generate revenue by performing complex cancer diagnostic tests for patients.
HemeScreen ProductSales of the HemeScreen testing panel to other hospitals and labs.They sell kits that allow other labs to perform their own genetic testing.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 15.43
Enterprise Value 39.79M
Price to Sales(TTM) 1.43
Enterprise Value 39.79M
Price to Sales(TTM) 1.43
Enterprise Value to Revenue 1.43
Enterprise Value to EBITDA 49.74
Shares Outstanding 1.79M
Shares Floating 1.41M
Shares Outstanding 1.79M
Shares Floating 1.41M
Percent Insiders 13.07
Percent Institutions 19.49

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.